Kilannin Krysiak.jpg

Kilannin Krysiak, PhD

Department of Medicine
Oncology Division
Stem Cell Biology

Research Interests

  • Precision medicine
  • Cancer genomics
  • Lymphoma


  • 314-747-9284 (tel)
  • McDonnell Genome Institute
Washington University School of Medicine
    Campus Box 8501
    4444 Forest Park Avenue
    St. Louis, MO 63108


My primary research interest is the improvement of patient treatment by advancing our understanding of the impact of specific genetic alterations on cancer prognosis and treatment response. I am involved in analysis and interpretation of sequencing data derived from cancers in large cohort and case studies as well as the development of resources designed to improve this process.

In collaboration with Todd Fehniger and Nancy Bartlet, we are investigating the genomic landscape of follicular lymphoma (FL) and the clinical implications of recurrent variants observed in this indolent non-Hodgkin lymphoma. Through targeted RNA and DNA sequencing, we are elucidating the pathways and mutations promoting lymphoma development as well as mechanisms of therapeutic resistance.

I have been involved in the development and curation of an open-source knowledgebase known as CIViC (Clinical Interpretation of Variants in Cancer, www.civicdb.org). The major goal of CIViC is collaborative evaluation and dissemination of clinically relevant interpretations of genetic alterations in cancer. The knowledgebase provides both human-readable and structured content to allow for programmatic access, cross-resource integration, transparency, and up-to-date interpretations from an interdisciplinary team of users. As an expert editor and development consultant, I lead collaborative efforts with other researchers in academic and commercial environments to improve the content and applications of this knowledgebase.

Other projects include ad hoc analyses of case studies to investigate novel research questions or guide clinical action involving cancer or cancer-predisposition as part of the Washington University Genomics Tumor Board. Additional ongoing cohort-level projects include analysis of relapsed small cell lung cancer, non-cirrhotic hepatocellular carcinoma and a mouse breast cancer model. These cohort studies improve our understanding of these cancers as well as provide a platform for additional resource development.